Supplementary Materials

Supplementary Material for:

Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes

Mohammad Alhadj Ali, Yuk-Fun Liu, Sefina Arif, Danijela Tatovic, Hina Shariff, Vivienne B. Gibson, Norkhairin Yusuf, Roman Baptista, Martin Eichmann, Nedyalko Petrov, Susanne Heck, Jennie H. M. Yang, Timothy I. M. Tree, Irma Pujol-Autonell, Lorraine Yeo, Lucas R. Baumard, Rachel Stenson, Alex Howell, Alison Clark, Zoe Boult, Jake Powrie, Laura Adams, Florence S. Wong, Stephen Luzio, Gareth Dunseath, Kate Green, Alison O'Keefe, Graham Bayly, Natasha Thorogood, Robert Andrews, Nicola Leech, Frank Joseph, Sunil Nair, Susan Seal, HoYee Cheung, Craig Beam, Robert Hills, Mark Peakman,* Colin M. Dayan

*Corresponding author. Email: mark.peakman{at}kcl.ac.uk

Published 9 August 2017, Sci. Transl. Med. 9, eaaf7779 (2017)
DOI: 10.1126/scitranslmed.aaf7779

This PDF file includes:

  • Fig. S1. Enrollment, randomization, and follow-up of study subjects.
  • Fig. S2. Representative flow cytometry gating strategy for Treg subsets.
  • Fig. S3. Representative flow cytometry gating strategy for antigen-specific CD8 T cells.
  • Table S1. Trial primary and secondary end points.
  • Table S2. Normalized C-peptide AUC at baseline and 3, 6, 9, and 12 months after initiation of treatment.
  • Table S3. Percentage change in daily insulin use (unit/kilogram) at baseline and 3, 6, 9, and 12 months after initiation of treatment.
  • Table S4. Change in daily insulin use (unit/kilogram) at baseline and 3, 6, 9, and 12 months after initiation of treatment.
  • Table S5. Percentage change in HbA1c (mmol/mol) at baseline and 3, 6, 9, and 12 months after initiation of treatment.
  • Table S6. Change in HbA1c (mmol/mol) at baseline and 3, 6, 9, and 12 months after initiation of treatment.
  • Table S7. In vitro response to proinsulin (or diluent control) according to C-peptide response status in peptide-treated subjects.
  • Table S8. Percentage change in Treg FOXP3 and Helios MFI from baseline at months 3 and 12.
  • Table S9. Percentage of CD57+ β cell–specific CD8 T cells at baseline and 6 months after initiation of treatment.
  • Table S10. In vitro response to proinsulin peptide C19-A3.
  • Table S11. Autoantibody levels at baseline and 6 and 12 months.
  • Table S12. In vitro response to recall antigen according to treatment group and C-peptide response.
  • Table S13. Analysis of proinsulin/C-peptide ratio in peptide-treated C-peptide responders and nonresponders.

[Download PDF]